LEO Pharma Reports 32-Week Results from a Post-hoc Analysis of Adbry (tralokinumab-ldrm) in P-III (ECZTRA 3) Trial for Atopic Dermatitis
Sots:
- The P-III (ECZTRA 3) trial evaluates tralokinumab-ldrm (300mg) + TCS in 380 adult patients with AD
- The results showed an improvement in extent & severity of AD, sleep interference & QoL @32wks., 70.2% of patient achieved improvement of ≥75% & 50.4% in EASI-75 & EASI-90; 70.8% in weekly avg. Eczema-related Sleep Interference NRS; 66.8% in DLQI over baseline. The results were published in American Journal of Clinical Dermatology
- At 16wk., 89.9% achieved an improvement in one of three disease measures incl. AD extent & severity (≥50% improvement in EASI-50); pruritus (≥3-point in weekly average Worst Daily Pruritus NRS); QoL (≥4-point in DLQI score), 75.3% achieved EASI-50 with improvements in pruritus or QoL
Ref: Bussinesswire | Image: LEO Pharma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
